Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from OS Therapies Incorporated ( (OSTX) ).
On September 2, 2025, OS Therapies completed a warrant exercise inducement and exchange offer, raising approximately $3.7 million in gross proceeds. This funding will accelerate the commercial launch preparations for OST-HER2 in the U.S., aimed at preventing or delaying recurrent osteosarcoma. The transaction involved exchanging existing warrants for new ones with a higher exercise price, potentially reducing short selling and allowing for additional capital influx if the company’s strategy succeeds. This positions OS Therapies to potentially commercialize OST-HER2 in early 2026, subject to FDA approval, and supports further development of their pipeline, including OST-504 for prostate cancer.
The most recent analyst rating on (OSTX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.
Spark’s Take on OSTX Stock
According to Spark, TipRanks’ AI Analyst, OSTX is a Underperform.
OS Therapies Incorporated faces significant financial difficulties, marked by increasing net losses, negative cash flows, and reliance on external financing. The technical analysis indicates bearish momentum with the stock trading below its moving averages. Valuation is challenging with no earnings to support a P/E ratio or dividend yield. These factors contribute to a low overall stock score, reflecting the company’s financial instability and negative market sentiment.
To see Spark’s full report on OSTX stock, click here.
More about OS Therapies Incorporated
OS Therapies is a clinical-stage oncology company focused on developing and commercializing treatments for osteosarcoma and other solid tumors. Their lead product, OST-HER2, is an immunotherapy that has received various designations from the U.S. FDA and European Medicines Agency, indicating its potential in treating recurrent, fully resected pulmonary metastatic osteosarcoma. The company is also advancing its Antibody Drug Conjugate (ADC) platform.
Average Trading Volume: 614,464
Technical Sentiment Signal: Strong Buy
Current Market Cap: $76.22M
For detailed information about OSTX stock, go to TipRanks’ Stock Analysis page.